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increase, the situation of cases with Boutonneuse fever dur-
ing last 15 years were:
Year - (No. of cases) 1991 - (3); 1992 - (6); 1993 - (12);
1994 - (26); 1995 - (24); 1996 - (27); 1997 - (21); 1998 - (30);
1999 - (68); 2000 - (13); 2001 - (30); 2002 - (17); 2003 - (14);
2004 - (16); 2005 - (99); 2006 - (61); 2007 - (25)
Conclusions: The monthly distribution of this disease
reﬂects seasonality of this affection, according with max-
imum period of thick spreading and human contact with
them. The year 2001 as 2000 register in June, especially
July and August the pick of morbidity, according to period of
maximum spread of ticks and human contacts with them and
for these years temperatures over the multiannual average.
doi:10.1016/j.ijid.2008.05.378
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Background: The Quadrivalent HP Recombinant Vaccine,
GardasilTM was approved in Canada in July 2006 and has been
in use since September 2006. Gardasil is offered to females
between 9 and 26 years of age. The aim of this vaccine is
to prevent the diseases associated with HPV types 6, 11,
16, 18 (cervical cancer and anogenital warts). Some juris-
dictions have already included this vaccine in their school
based immunization program.
Methods: All Adverse Event Following Immunization
reports received by the Public Health Agency of Canada
through passive and active surveillance programs were
reviewed and included in the analysis.
Results: A total of 148 reports of AEFI was received by the
Agency between September 2006 and December 2007, with a
reporting rate estimated at 38/100,000 doses distributed. In
majority of cases (97.4%) HPV vaccine was the only vaccine
given.
The age ranged from 10 to 45 years old with median at
18.0 and StD 5.8 years.
The most commonly reported AEFIs were injection site
pain (20%), other injection site reactions (8%), nausea
(8%); dizziness, headache, rash and vomiting (each 7.5%),
urticaria (7%); and diarrhea, fever, rash and syncope (each
6%). There were two reports of serious AEFIs - one anaphy-
lactic reaction and one encephalopathy.
Medical attention was sought by 51 cases (35%), including
4 hospitalizations, 10 emergency room visits and 37 outpa-
tient visits. The outcome was reported in 58 reports (40%),
of which 41 reported full recovery, 10 recovering, and 7
reported some residual effect at the time of reporting.
Conclusion: Gardasil is considered a safe vaccine in
Canada. AEFIs reported following this vaccine were mainly
minor injection site reactions and mild systemic events.
AEFI data collected through the Canadian active and pas-
sive surveillance programs have been consistent with the
data obtained from the pre-licensure clinical trials.
doi:10.1016/j.ijid.2008.05.379
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Background: Safety and reactogenicity of the candidate
10-valent Pneumococcal non-typeable Haemophilus inﬂuen-
zae Protein D-conjugate vaccine (PHiD-CV, GlaxoSmithKline
Biologicals), designed to protect infants against pneumo-
coccal and non-typeable Haemophilus inﬂuenzae diseases,
were evaluated when co-administered with DTPw-HBV/Hib
and OPV vaccines at 6—10—14 weeks of age (EPI schedule)
in the Philippines.
Methods: In this double-blind, controlled study
(107007/NCT00344318), 400 healthy Filipino infants 6
to 12 weeks old were randomized (3:1) to receive either
PHiD-CV or licensed 7vCRM vaccine (PrevenarTM/PrevnarTM),
both co-administered with DTPw-HBV/Hib +OPV. Solicited
local (pain, redness, swelling), general (fever, drowsiness,
irritability, loss of appetite) and unsolicited symptoms as
well as serious adverse events (SAEs) were recorded after
each vaccination. Intensity was assessed on a scale from
1—3.
Results: The most frequently reported solicited local
grade 3 symptoms were pain following 9.4% of vaccine
doses in both groups and swelling following 9.3% (PHiD-
CV) and 8.1% (7vCRM) vaccine doses. Irritability was the
most frequently reported solicited general grade 3 symptom
following 2.9% (PHiD-CV) and 2.4% (7vCRM) vaccine doses.
Observed overall/dose incidence of fever (rectal temper-
ature ≥38 ◦C) was within the same range in both groups
(PHiD-CV: 60.9%; 7vCRM: 63.0%) with no cases of rectal fever
>40 ◦C. Seven infants reported at least one SAE: 6 in the
PHiD-CV group and 1 in the 7vCRM group. None of them
was assessed by the investigator to be causally related to
vaccination and all resolved without sequelae.
Conclusion: No clinically relevant differences were
observed between the safety and reactogenicity proﬁles of
PHiD-CV and 7vCRM vaccines.
doi:10.1016/j.ijid.2008.05.380
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Background: Measles has been universally known as a
major child health problem and a killer of children mainly
